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Background:  Drug-eluting-stents  (DES)  reduce  clinical  restenosis,  but  have  mostly  failed  to demonstrate  a
reduction  in death  or myocardial  infarction.  The  aim  of  this  study  was  to evaluate  the  prognostic  impact  of
the  introduction  of DES  in  patients  undergoing  multivessel  percutaneous  coronary  intervention  (MV-PCI).
Methods:  Survival  was  assessed  in  679  consecutive  patients,  who  underwent  PCI  in  at  least  two  main
vessels.  Follow-up  was  available  in  667  patients  (98%)  with  a mean  follow-up  of  4.8  ± 2.5  years.  We
compared  several  scenarios:  ﬁrstly,  patients  receiving  at least  one  DES  (≥1  DES  group)  vs. bare  metal  stent
(BMS)-only  patients  (BMS  only);  secondly,  the  population  was  divided  into  a pre-DES-era  (2000–2003;
N  =  257)  and  a DES-era  (2004–2006;  N  =  422).
Results:  316  patients  (47%)  were  treated  for acute  myocardial  infarction  (MI; N =  176  ST-elevation  MI;
N =  140  non-ST-elevation  MI).  On  average,  2.2 ± 0.4 vessels  were  treated  and  212  patients  received  at least
one DES.  The  DES  group  showed  a higher  number  of  diseased  (2.5  ± 0.6  vs. 2.4 ± 0.5;  p  = 0.02)  and  treated
vessels  (2.2  ±  0.5  vs. 2.1 ± 0.3;  p < 0.01)  and  received  more  stents  (3.3  ± 1.4 vs.  3.0 ± 1.1;  p  <  0.01).  The
BMS  group  presented  more  frequently  with  acute  MI  (55%  vs.  29%;  p  < 0.01).  The  DES  group  showed  more
complex  disease  as  evidenced  by a higher  SYNTAX-Score  (17.4  ±  8.5  vs.  14.5  ± 8.3;  p  < 0.01).  Restricting
the  survival  analysis  to patients  with  stable  coronary  artery  disease,  a signiﬁcant  prognostic  advantage
was  found  for  patients  received  at least  one  DES  compared  to the BMS  group  (hazard  ratio  0.58,  95%
conﬁdence  interval  0.34–0.99)  in  the  multivariate  cox-regression-analysis.
Conclusion:  The  introduction  of  DES  leads  to extension  of  treatment  to more  complex  patients.  The use
 impr
2  Japof  DES  is  associated  with
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In recent years the long-term safety of drug-eluting stents (DES)
as been evaluated by various studies. Indeed, it has been demon-
trated that DES reduce rates of clinical restenosis and of target
esion revascularization (TLR) compared to bare metal stents (BMS).
owever, this apparently does not translate into a beneﬁt on hard
linical endpoints, since the majority of studies failed to show a
eduction in death or myocardial infarction (MI), compared with
onventional BMS  [1–8].Some authors even reported an increased rate of death in asso-
iation with DES compared with BMS  due to an increased rate of
ery late stent thrombosis [9–11]. Opposite to these results some
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studies showed a survival beneﬁt with DES [12], but these results
were mostly restricted to speciﬁc clinical situations [13]. In addi-
tion, the optimal concomitant therapy especially duration of dual
antiplatelet therapy receiving DES remains controversial [14].
A Chinese study from 2010 reported a signiﬁcant reduction in
the cumulative 3-year rates of all-cause mortality, cardiovascular
death, and MI  associated with the implantation of DES [15]. How-
ever, percutaneous coronary intervention (PCI) procedures had
been predominantly performed on a single vessel in those studies,
whereas complete revascularization was not pursued as a treat-
ment goal.
We  assumed that a possible prognostic impact of DES is greater
in patients undergoing multivessel PCI (MV-PCI) rather than sin-
gle vessel PCI. For this reason, the aim of the present study was
to evaluate whether use of DES during MV-PCI is associated with
a clinical advantage over BMS  in patients undergoing extended
revascularization. Foremost, the present study is the ﬁrst to report
on long-term clinical outcome in patients treated with MV-PCI on
an “all-comers” basis.
vier Ltd. All rights reserved.
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ethods
haracteristics of the study – main objective
The aim of our retrospective study was to evaluate the progno-
tic impact of MV-PCI with use of DES on long-term survival.
tudy population – inclusion criteria
A total number of 679 consecutive patients undergoing coro-
ary stent implantation in at least two main vessels [left anterior
escending artery (LAD), right coronary artery (RCA), left circum-
ex artery (LCX), ramus intermedius (RIM), left main coronary
rtery (LMCA)] during one session at the University Hospital of
rankfurt, Germany were included in this study. The population
as been previously described [16,17]. All patients were treated
etween August 2000 and December 2006 (almost 6000 PCI pro-
edures were performed in total within the same period at our
enter). The general interventional strategy at the institution is
ommonly aimed at treating all ischemia-inducing lesions in one
ession. The main reasons favoring DES in the study period were PCI
f prognostically relevant (proximal) segments, elevated perceived
isk of restenosis due to patient-related factors (e.g. diabetes, his-
ory of restenosis due to previous PCI, chronic renal failure) or
rocedural factors (e.g. long lesions, small diameter of the target
essel, bifurcation lesion). However, the ﬁnal choice was left to the
esponsible operator.
tudy population – exclusion criteria
All patients with previous CABG were excluded.
rocedures
Clinical data were acquired from medical history and reports
f diagnostic testing including blood tests. All records and inter-
entional protocols were systemically reviewed. The cohort was
rouped into different pairs of patients representing different sce-
arios:
1) 457 patients were treated with BMS  only while 210 patients
received at least one DES (≥1 DES-group).
2) 69 patients received DES exclusively while 598 patients were
treated with at least one BMS  (≥1 BMS-group).
3) The population was stratiﬁed into a pre-DES-era (2000–2003;
N = 257) and a DES-era (2004–2006; N = 422) group.
4) To conﬁrm the prognostic relevance of DES and in an attempt
to avoid any bias related to differences in the extension of the
ischemic region on the clinical outcome, the same analysis as in
point 1 was restricted to the subpopulation of patients receiving
PCI of a proximal prognostic relevant segment (Segments 1, 5,
6, 11; de novo only).
Given the higher rate of BMS  implantation in patients with acute
oronary syndrome (caused by the restrictive usage in this indica-
ion especially in the ﬁrst years of the study period) an additional
nalysis restricted to the subpopulation of the stable patients was
erformed for all four groups.
Stable coronary artery disease (CAD) was deﬁned by the absence
f dynamic elevated cardiac enzymes in 72 h prior to catheter-
zation (N = 362). The remaining patients received MV-PCI in the
etting of an acute coronary syndrome, coinciding with an eleva-
ion in cardiac enzymes [N = 140 non ST-elevation MI  (NSTEMI);
 = 177 ST-elevation MI  (STEMI)].diology 61 (2013) 38–43 39
Follow-up
Survival was  primarily assessed by telephone calls (patients,
relatives, physicians) or through a query to the resident’s registra-
tion ofﬁce. All telephone follow-ups were performed between June
2009 and November 2010. In those cases where the needed infor-
mation was  not available through telephone interview, the local
resident’s registration ofﬁce or the patient’s general practitioner
the last date on which the patient was seen alive was included in
our analysis.
Vital status was  available in 667 (98%) patients with a mean-
follow up of 4.8 ± 2.5 years.
Statistics
Data are expressed as percentages for discrete variables and
as mean ± SD for continuous variables. Continuous variables were
compared by the Mann–Whitney U test (two-sided). A multi-
variable Cox-regression-analysis was performed, analyzing the
inﬂuence of DES usage according to the different predeﬁned groups
on survival compared to clinical and procedural factors. Study end-
point was  all-cause mortality in line with the most important major
European registries such as the Swedish Coronary Angiography and
Angioplasty Registry (SCAAR) [9] and Denmark Heart Registry [3].
All calculations were performed ﬁrst as univariate analysis and
included only categorical variables. Therefore continuous variables
were dichotomized. Hazard ratios (HR) and 95% conﬁdence inter-
vals (CIs) were calculated.
All parameters that reached statistical signiﬁcance (p < 0.05)
in the univariate Cox-regression-analysis were entered into the
multivariate algorithm. HR and 95% CIs were calculated for each
factor. Long-term clinical adverse events were compared by
Kaplan–Meier (KM) survival curves, and the corresponding p-
values were obtained from the log-rank test. Statistical signiﬁcance
was assumed at p < 0.05. All statistical analyses were performed
using SPSS for Windows 19.0.
Results
Baseline characteristics
The baseline clinical, angiographic, and procedural character-
istics of the total study population are summarized in Table 1,
separately for the ≥1 DES-group and BMS-only group. Table 2 pro-
vides the same information for the subgroup of patients with stable
CAD.
The majority of patients in our study population (N = 467; 69%)
was treated with BMS  compared to 212 patients receiving at least
one DES.
Left ventricular ejection fraction was  lower in the ≥1 DES-
group (severely reduced 57.5% vs. 39.4%; p < 0.001). In addition,
patients with DES were treated less frequently for acute coro-
nary syndromes (NSTEMI/STEMI 29.2% vs. 54.6% p < 0.001). A higher
number of patients included in the ≥1 DES group presented with
three-vessel-disease (55.2 vs. 42.0%; p < 0.001) and received three-
vessel-treatment to a greater extent (24.5% vs. 12.2; p < 0.001).
Patients in the ≥1 DES group had been treated with LMCA-PCI
nearly 10 times more frequently (18.9% vs. 2.1%; p < 0.001).
Furthermore, total stent length (56 ± 29 mm vs. 47 ± 21 mm;
p < 0.001) was signiﬁcantly higher in the ≥1 DES group. The higher
anatomical risk of the ≥1 DES group is also conﬁrmed by the higher
SYNTAX-Score observed (17.4 ± 8.5 vs. 14.5 ± 8.3; p < 0.001). On  the
contrary, the EuroSCORE, a widely used peri-procedural clinical risk
predictor was lower in the ≥1 DES group (9.7 ± 12.5 vs. 7.8 ± 12.0;
p < 0.001).
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Table 1
Baseline characteristics at least 1 DES vs. BMS-only; all patients.
BMS  only N = 467 ≥1 DES N = 212 p-Value
Age (years) 64.4 ± 11.7 65.7 ± 10.5 0.182
Female gender 119 (25.5%) 37 (17.5%) 0.013
LVEF severely reduced 184 (39.4%) 122 (57.5%) <0.001
Log.  EuroSCORE 9.7 ± 12.5 7.8 ± 12.0 0.062
SYNTAX-Score 14.5 ± 8.3 17.4 ± 8.5 <0.001
Killip IV ACS 36 (7.7%) 9 (4.2%) 0.061
Stable CAD 212 (45.4%) 150 (70.8%) <0.001
NSTEMI 101 (21.6%) 39 (18.4%) <0.001
STEMI 154 (33.0%) 23 (10.8%) <0.001
Diabetes mellitus 126 (27.0%) 67 (31.6%) 0.126
Chronic renal failure 28 (6.0%) 14 (6.6%) 0.440
History of prior PCI 103 (22.1%) 96 (45.3%) <0.001
3-vessel disease 196 (42.0%) 117 (55.2%) 0.001
3-vessel treatment 57 (12.2%) 52 (24.5%) <0.001
LMCA-PCI 10 (2.1%) 40 (18.9%) <0.001
No.  of diseased vessels 2.4 ± 0.5 2.7 ± 0.7 <0.001
No.  of treated vessels 2.1 ± 0.3 2.3 ± 0.5 <0.001
No.  of occluded vessels 0.5 ± 0.7 0.4 ± 0.6 0.093
No.  of treated lesions 2.8 ± 0.9 3.0 ± 1.1 0.011
No.  of implanted stents 3.2 ± 1.2 3.4 ± 1.5 0.062
Total stent length (mm) 47.3 ± 21.3 56.3 ± 28.6 <0.001
Patients with DES only 0 70 (33%)
DES, drug-eluting stent; BMS, bare metal stent; LVEF, left ventricular ejection frac-
tion; ACS, acute coronary syndrome; CAD, coronary artery disease; NSTEMI, non
ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction; PCI,
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Table 3
Medication at discharge.
BMS  only ≥1 DES p-Value
Entire population
Statin 88% 96% 0.001
ACE  inhibitors 88% 80% 0.011
ARB  9% 16% 0.010
Beta-blockers 96% 96% 0.832
Aspirin 96% 97% >0.999
Clopidogrel 100% 100% n.a.
Oral  anticoagulants 8% 10% 0.355
Stable patients
Statin 88% 95% 0.022
ACE  inhibitors 84% 76% 0.100
ARB  12% 19% 0.097
Beta-blockers 95% 94% 0.819
Aspirin 96% 97% 0.784
Clopidogrel 100% 100% n.a.
Oral  anticoagulants 8% 11% 0.354ercutaneous coronary intervention; LMCA, left main coronary artery.
Looking at the subpopulation of patients presenting with stable
AD, baseline characteristics were similar among the BMS  and the
ES groups (Table 2). However, SYNTAX-Score, number of diseased
essels, proportion of LMCA-PCI and total stent length showed a
igniﬁcantly higher risk proﬁle in the ≥1 DES group (Table 2).
Patients were on optimal medical therapy at discharge with
00% on clopidogrel, 96% on beta-blockers, and 90% on statin ther-
py (Table 3). Remarkable is the signiﬁcant higher rate of statin
herapy in the ≥1 DES group (96%) compared to the BMS-group
88%; p = 0.001). It is still true when analysis was restricted to the
table patients. This is opposed to angiotensin-converting enzyme
nhibitors and angiotensin receptor blockers, where the different
roportion of treatment can only be shown in the entire population
ue to more heart failure patients in the ≥1 DES group.
able 2
aseline characteristics at least 1 DES vs. BMS-only, stable CAD.
BMS  only N = 212 ≥1 DES N = 150 p-Value
Age (years) 64.4 ± 11.4 64.8 ± 10.0 0.722
Female gender 51 (24.1%) 24 (16.0%) 0.066
LVEF severely reduced 27 (12.7%) 15 (10.0%) 0.506
Log.  EuroSCORE 4.2 ± 4.6 3.5 ± 3.5 0.091
SYNTAX-Score 12.0 ± 6.7 16.5 ± 8.0 <0.001
Diabetes mellitus 56 (26.4%) 53 (35.3%) 0.081
Chronic renal failure 12 (5.7%) 7 (4.7%) 0.812
History of PCI 65 (30.7%) 80 (53.3%) <0.001
3-vessel disease 80 (37.7%) 78 (52.0%) 0.007
3-vessel treatment 23 (10.8%) 33 (22.0%) 0.005
LMCA-PCI 2 (0.9%) 24 (16.0%) <0.001
No.  of diseased vessels 2.4 ± 0.5 2.6 ± 0.6 <0.001
No.  of treated vessels 2.1 ± 0.3 2.3 ± 0.5 0.001
No.  of occluded vessels 0.3 ± 0.6 0.4 ± 0.6 0.110
No.  of treated lesions 2.7 ± 0.8 2.9 ± 1.0 0.064
No.  of implanted stents 3.0 ± 1.1 3.2 ± 1.4 0.097
Total stent length (mm) 43.5 ± 20.1 54.8 ± 28.0 <0.001
Patients with DES only 0 60 (40%)
ES, drug-eluting stent; BMS, bare metal stent; LVEF, left ventricular ejection frac-
ion; CAD, coronary artery disease; PCI, percutaneous coronary intervention; LMCA,
eft main coronary artery.DES, drug-eluting stent; BMS, bare metal stent; ACE, angiotensin-converting
enzyme; ARB, angiotensin receptor blocker.
Long-term survival following MV-PCI
Analysis of the entire cohort, including both stable CAD and
acute coronary syndrome patients, showed no difference on long-
term mortality between ≥1 DES vs. BMS  only (p = 0.101), or between
DES only vs. ≥1 BMS  (p = 0.116) (Fig. 1).
In addition, no signiﬁcant difference in long-term mortality was
observed between the pre-DES and the DES-era groups, despite the
higher anatomical and clinical risk characterizing patients treated
in the DES era (p = 0.260).
Foremost, a signiﬁcant prognostic advantage was observed for
the ≥1 DES group, as compared to the BMS-only group, after
restricting the survival-analysis to patients with stable CAD (see
KM-curve: p log rank 0.029; HR 0.57, 95%CI 0.34–0.95; Fig. 2). More-
over, a trend toward a higher survival could be shown in patients
treated with DES exclusively (p log rank 0.150; HR 0.57, 95%CI
0.26–1.24).
In order to identify independent predictors for long-term mor-
tality within the DES group a Cox-regression-analysis restricted to
stable CAD patients was  performed (Table 4). Interestingly, use of
DES (at least one DES implanted in the context of a MV-PCI) was
associated with a 42% mortality reduction upon multivariate anal-
ysis (HR 0.58; 95%CI 0.34–0.99). Further independent predictors
of long-term mortality upon multivariate analysis were diabetes
(HR 2.02; 95%CI 1.27–3.22), severely reduced LVEF (HR 2.32; 95%CI
1.26–4.29), chronic renal failure (HR 2.53; 95%CI 1.15–5.56), and
statin therapy at discharge (HR 0.48; 95%CI 0.26–0.88).
Table 4
Cox-regression analysis (stable patients); event: all-cause mortality.
Univariate Multivariate
Age > 60 years 1.95 (1.13–3.36) 1.70 (0.96–3.03)
LVEF severely reduced 2.94 (1.72–5.03) 2.32 (1.26–4.29)
Female gender 1.01 (0.59–1.73) –
Chronic renal failure 2.36 (1.09–5.13) 2.53 (1.15–5.56)
Diabetes 1.97 (1.27–3.06) 2.02 (1.27–3.22)
3-vessel disease 1.28 (0.83–1.98) –
3-vessel treatment 0.88 (0.45–1.71) –
LMCA-PCI 1.11 (0.45–2.75) –
No  of implanted stents 0.94 (0.78–1.14) –
Total stent length (per 10 mm)  0.86 (0.55–1.35) –
Usage of DES 0.57 (0.34–0.95) 0.58 (0.34–0.99)
Pre-DES era 1.01 (0.63–1.61) –
Statin therapy at discharge 0.41 (0.23–0.75) 0.48 (0.26–0.88)
LVEF, left ventricular ejection fraction; LMCA, left main coronary artery; PCI, percu-
taneous coronary intervention; DES, drug-eluting stent.
T. Schwietz et al. / Journal of Cardiology 61 (2013) 38–43 41
Fig. 1. Kaplan–Meier analysis (all patients; event: all-cause-mortality). DES, drug-eluting stent; BMS, bare metal stent; PCI, percutaneous coronary intervention.
Fig. 2. Kaplan–Meier–analysis (stable coronary artery disease; event: all-cause-mortality). DES, drug-eluting stent; BMS, bare metal stent; PCI, percutaneous coronary
intervention.
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iscussion
The two main ﬁndings of the present study are: (a) intro-
uction of DES into clinical catheterization laboratory routine
as been associated with extension of PCI to more complex
esion sets and higher risk patients, without any signiﬁ-
ant increase in long-term mortality, as compared to the
ower-risk patients group treated with BMS  only; (b) patients
ith stable multi-vessel CAD treated with at least one DES
how a lower long-term mortality than those treated with
MS  only, which is also the major novelty of the present
ork.
Findings from some studies suggested even an increasing inci-
ence of cardiac death and all-cause mortality related to DES
mplantation [9–11]. However, giving the highly selected pop-
lation included in those studies, a selection bias has been
laimed to account for the high mortality observed especially
n the group of patients treated with DES, making extrapola-
ions to the general population quite difﬁcult. On the other
and, the population included in the present study represents
n unselected “all-comers” cohort with predeﬁned extended dis-
ase. All consecutive patients undergoing MV-PCI have been
ncluded.
When dividing the study cohort on the basis of treatment
trategy, patients treated with DES featured a higher SYNTAX-
core, presented more frequently with three-vessel CAD, treatment
f three-vessel disease and LMCA in comparison to BMS only
reated patients. Also, the number of diseased and treated vessels
nd total stent length was signiﬁcantly higher in the DES group
Table 1), indicating a higher anatomical risk in comparison with
he BMS  group. Indeed, these data document that implementation
f DES lead to extension of treatment to more complex lesions and
atients.
According to the KM-curves (Fig. 2) DES-PCI was  associated
ith an improved survival compared with BMS-PCI (p < 0.001)
n stable patients, which also can be shown in the multivariate
ox-regression-analysis (Table 4). Despite the higher anatomical
isk shown by the SYNTAX-Score, the clinical risk was simi-
ar evidenced by the EuroSCORE (Table 2). No difference was
etected in the survival of patients treated in the era of DES
ompared with the pre-DES era independent from ﬁnal stent
hoice. Therefore an “era bias” with potentially better progno-
is of patients treated with more extensive experience can be
xcluded.
Usage of DES in stable patients was associated with a pro-
ounced mortality risk reduction in the population of the present
tudy. These results complement similar ﬁndings from previous
tudies which were restricted to acute patients [13]. More-
ver in our study, diabetes mellitus, chronic renal failure and
everely reduced left ventricular ejection fraction, which are
ell known predictors for worse outcome of CAD patients,
ere independently associated with a doubled to tripled risk of
ortality.
In summary, our data indicate the extension of treatment to
ore complex disease after the introduction of DES. This single-
enter registry is the ﬁrst study suggesting a survival beneﬁt of
ES in MV-PCI.
imitations
There are intrinsic limitations to the data due to the design
s a retrospective non-randomized study: First, differences in not
valuated baseline characteristics cannot be excluded. Addition-
lly, selection bias due to the restriction of patients undergoing
V-PCI and due to the non-randomized assigning to different treat-
ent strategies (DES vs. BMS) might be possible. Furthermore, the
[diology 61 (2013) 38–43
primary study endpoint was all-cause mortality. No systematic
evaluation of the cause of death (cardiac vs. non-cardiac death)
was performed. This is in line with the most important major
European registry surveys of Swedish Coronary Angiography and
Angioplasty Registry (SCAAR) and Denmark Heart Registry. In addi-
tion only all-cause mortality covers potential fatal adverse events
caused by prolonged dual antiplatelet therapy and others. Due to
these limitations it could be discussed that the conclusion might
be restricted to the fact that the introduction of DES makes treat-
ment of more complex patients with multivessel disease possible
and, it is deﬁnitely not associated with adverse outcomes regarding
long-term mortality. Usage of DES is even associated with improved
survival.
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